ConductScience.org, home

Paper35923716

FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms.

Acharya B and 4 others. RSC Med Chem, 2022. Cited by 29 papers, by iCite.

Cite this record

ConductScience Library. FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms. Papers, record 35923716. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35923716

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms.
PubMed
Journal
RSC Med Chem
PubMed
Year
2022
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
29
iCite
Relative citation ratio, by iCite
2.2
iCite
Revised in PubMed
2024-09-01
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Acharya BBaku
2Saha DDebasmita
3Armstrong DDaniel
4Lakkaniga NRNaga Rajiv
5Frett BBrendanhttps://orcid.org/0000-0003-2429-8895

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P20 GM109005NIGMS NIH HHSUnited StatesP20GM109005PubMed

Source NIH RePORTER

Download CSV of grants

References122

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112239147
Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors.
Blood2002https://conductscience.org/library/papers/12239147PubMed
214985312Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412.Invest Ophthalmol Vis Sci2004https://conductscience.org/library/papers/14985312PubMed
323631653FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations.Leuk Lymphoma2014https://conductscience.org/library/papers/23631653PubMed
428516360Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.Invest New Drugs2017https://conductscience.org/library/papers/28516360PubMed
531088841Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.Cancer Discov2019https://conductscience.org/library/papers/31088841PubMed
630651634Targeting FLT3 mutations in AML: review of current knowledge and evidence.Leukemia2019https://conductscience.org/library/papers/30651634PubMed
710573574Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia.Med Pediatr Oncol1999https://conductscience.org/library/papers/10573574PubMed
87537980FLT3/FLK2 ligand promotes the growth of murine stem cells and the expansion of colony-forming cells and spleen colony-forming units.Blood1995https://conductscience.org/library/papers/7537980PubMed
931821677FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.Cancer Sci2020https://conductscience.org/library/papers/31821677PubMed
108929245Antitumor activity of the new selective protein kinase C inhibitor 4'-N-benzoyl staurosporine on murine and human tumor models.Arzneimittelforschung1995https://conductscience.org/library/papers/8929245PubMed
1110888033PKC412--a protein kinase inhibitor with a broad therapeutic potential.Anticancer Drug Des2000https://conductscience.org/library/papers/10888033PubMed
1212124172CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).Cancer Cell2002https://conductscience.org/library/papers/12124172PubMed
1331102119Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.Invest New Drugs2020https://conductscience.org/library/papers/31102119PubMed
148822090Antitumor effect of CGP41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells.Jpn J Pharmacol1996https://conductscience.org/library/papers/8822090PubMed
1528645776Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.Lancet Oncol2017https://conductscience.org/library/papers/28645776PubMed
1624623852Crenolanib is a selective type I pan-FLT3 inhibitor.Proc Natl Acad Sci U S A2014https://conductscience.org/library/papers/24623852PubMed
1712663439Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.Blood2003https://conductscience.org/library/papers/12663439PubMed
1817016424Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.Nat Rev Drug Discov2006https://conductscience.org/library/papers/17016424PubMed
1927931243Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.J Hematol Oncol2016https://conductscience.org/library/papers/27931243PubMed
203759657K-252a, a potent inhibitor of protein kinase C from microbial origin.J Antibiot (Tokyo)1986https://conductscience.org/library/papers/3759657PubMed

See all 122 referencesDownload CSV of references

Cited by19

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 29 citations.

PMIDTitleJournalYearIn PapersSource
42466468FLT3 inhibitors in AML: from classic scaffolds to next-generation approaches.RSC Adv2026https://conductscience.org/library/papers/42466468PubMed
42220773FLT3 Testing and Guideline Concordance in Acute Myeloid Leukemia Across a Community Health System.Cureus2026https://conductscience.org/library/papers/42220773PubMed
42131843CS-DTA: a language model-driven framework for robust drug-target affinity prediction under strict cold-start scenarios.Front Chem2026https://conductscience.org/library/papers/42131843PubMed
41954160Results of a Large-Scale Study of the Binding of 50 Type II Inhibitors to 348 Kinases: The Role of Protein Reorganization.J Med Chem2026https://conductscience.org/library/papers/41954160PubMed
41757266Structural pharmacogenomics of drug-associated SNPs in oral squamous cell carcinoma.Front Genet2026https://conductscience.org/library/papers/41757266PubMed
41676586Results of a large scale study of the binding of 50 type II inhibitors to 348 kinases: The role of protein reorganization.bioRxiv2026https://conductscience.org/library/papers/41676586PubMed
41557028Vascular complications in NPM1-Mutated acute myeloid leukemia: clinical features and prognosis.Ann Hematol2026https://conductscience.org/library/papers/41557028PubMed
40386346Razing the scaffolding: the elimination of non-catalytic functions of kinases through targeted protein degradation.RSC Med Chem2025https://conductscience.org/library/papers/40386346PubMed
40365393IRAK1/4/pan-FLT3 Kinase Inhibitors with Reduced hERG Block as Treatments for Acute Myeloid Leukemia.ACS Med Chem Lett2025https://conductscience.org/library/papers/40365393PubMed
39813774
The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN) and the FLT3 inhibitor gilteritinib (GIL) is more active in acute myeloid leukemia cells than novel polypharmacologic BCL-2/FLT3 VEN-GIL hybrid single-molecule inhibitors.
Eur J Med Chem2025https://conductscience.org/library/papers/39813774PubMed
39569127Recent studies on protein kinase signaling inhibitors based on thiazoles: review to date.RSC Adv2024https://conductscience.org/library/papers/39569127PubMed
39563805Discovery of IRAK1/4/pan-FLT3 Kinase Inhibitors as Treatments for Acute Myeloid Leukemia.ACS Med Chem Lett2024https://conductscience.org/library/papers/39563805PubMed
39263156Molecular precision medicine: Multi-omics-based stratification model for acute myeloid leukemia.Heliyon2024https://conductscience.org/library/papers/39263156PubMed
39091016Gilteritinib Reduces FLT3 Expression in Acute Myeloid Leukemia Cells.Biomol Ther (Seoul)2024https://conductscience.org/library/papers/39091016PubMed
38049337[Effect of clonal hematopoiesis in remission on hematopoiesis recovery in patients with NPM1 mutated acute myeloid leukemia after chemotherapy].Zhonghua Xue Ye Xue Za Zhi2023https://conductscience.org/library/papers/38049337PubMed
37892567A Review of FLT3 Kinase Inhibitors in AML.J Clin Med2023https://conductscience.org/library/papers/37892567PubMed
37438819Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia.BMC Chem2023https://conductscience.org/library/papers/37438819PubMed
36622782Mechanisms associated with t(7;12) acute myeloid leukaemia: from genetics to potential treatment targets.Biosci Rep2023https://conductscience.org/library/papers/36622782PubMed
36430695Flavones, Flavonols, Lignans, and Caffeic Acid Derivatives from Dracocephalum moldavica and Their In Vitro Effects on Multiple Myeloma and Acute Myeloid Leukemia.Int J Mol Sci2022https://conductscience.org/library/papers/36430695PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
FLT32322PubTator's text mininghttps://conductscience.org/library/genes/2322

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35923716

GET https://conductscience.org/api/papers/v1/35923716/references?page=2